Commenting on the financing, Dr John Tchlingrian, President and CEO said:

“We are delighted to have received this significant financial support from our world class investor group that continuously supported Diatos and its management team. The Company is now in a strong financial position with a deep and balanced portfolio of oncology products and assets. With this financing we will focus on taking our clinical and preclinical products forward to their next stage of maturity and achieve significant development and value creation milestones”.

Diatos is a biopharmaceutical company dedicated to the research, development and commercialization of innovative anti-cancer drugs with enhanced tumor targeting or improved biodistribution. Diatos is expanding its portfolio of drug candidates with new compounds that utilize its Vectocell delivery technology or its Tumor-Selective Prodrug (TSP) technology as well as with in-licensed candidate and marketed cancer therapies. Diatos is headquartered in Paris, France and operates subsidiaries in Belgium and the United States of America.

For further information, please visit www.diatos.com